Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

Inclusion Criteria:

- males and females 18 years of age or over

- diagnosis of adult GHD for at least 6 months, or patients who have hypopituitarism
from surgical resection

- treated with a stable dose of daily rhGH for at least 3 months prior to screening

- stable, adequate doses of replacement hormones (adrenal, thyroid, estrogen,
testosterone, vasopressin) for at least 3 months prior to screening

- Other criteria apply, please contact the investigator for more information

Exclusion Criteria:

- patients with acute or chronic conditions or diseases that could confound results of
the study or put the patient at undue risk as determined by the investigator

- Presence of contraindications to rhGH treatment

- patients who have participated in another clinical trial with a new
chemical/biological entity within 3 months of screening

- patients with known active malignancy (excluding surgically removed basal cell
carcinoma or carcinoma in situ of cervix) d. patients with a previously treated
pituitary tumor with evidence of tumor progression in the past year

- patients with a new diagnosis of pituitary adenoma or other intracranial tumor within
12 months of screening

- presence of Prader-Willi syndrome, Turner's syndrome, untreated adrenal
insufficiency, active acromegaly in the past 5 years, or active Cushing's syndrome in
the past year.

- patients with type 1 diabetes mellitus oror poorly controlled type 2 diabetes
mellitus as indicated by a glycated hemoglobin (HbA1c) ≥8%

- patients using weight reducing agents or appetite suppressants

- Other criteria apply, please contact the investigator for more information